These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 33484942)

  • 1. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
    El-Naggar AM; El-Hashash MA; Elkaeed EB
    Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity.
    Hamed OA; Abou-Elmagd El-Sayed N; Mahmoud WR; F Elmasry G
    Bioorg Chem; 2024 Jun; 147():107413. PubMed ID: 38696844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
    Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.
    Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM
    Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction.
    Nemr MTM; Elshewy A; Ibrahim ML; El Kerdawy AM; Halim PA
    Bioorg Chem; 2024 Sep; 150():107566. PubMed ID: 38896936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
    Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity.
    El-Sattar NEAA; Badawy EHK; AbdEl-Hady WH; Abo-Alkasem MI; Mandour AA; Ismail NSM
    Chem Pharm Bull (Tokyo); 2021; 69(1):106-117. PubMed ID: 33390512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
    Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
    Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
    Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA
    Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
    Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
    Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study on MAPK/ERK and CDK2-Cyclin-E signal switch "on and off" in cell proliferation by bis urea derivatives of 1, 4-Diisocyanatobenzene.
    Nagalakshmamma V; Venkataswamy M; Pasala C; Uma Maheswari A; Thyaga Raju K; Nagaraju C; Chalapathi PV
    Bioorg Chem; 2021 Jul; 112():104940. PubMed ID: 33965780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
    Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
    Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
    Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B
    Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity.
    Diao PC; Lin WY; Jian XE; Li YH; You WW; Zhao PL
    Eur J Med Chem; 2019 Oct; 179():196-207. PubMed ID: 31254921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities.
    Shawky AM; Ibrahim NA; Abourehab MAS; Abdalla AN; Gouda AM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):15-33. PubMed ID: 33103497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.
    Roy T; Boateng ST; Banang-Mbeumi S; Singh PK; Basnet P; Chamcheu RN; Ladu F; Chauvin I; Spiegelman VS; Hill RA; Kousoulas KG; Nagalo BM; Walker AL; Fotie J; Murru S; Sechi M; Chamcheu JC
    Bioorg Chem; 2021 Feb; 107():104595. PubMed ID: 33450548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia.
    Almehmadi SJ; Alsaedi AMR; Harras MF; Farghaly TA
    Bioorg Chem; 2021 Dec; 117():105431. PubMed ID: 34688130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, Docking Studies into CDK-2 and Anticancer Activity of New Derivatives Based Pyrimidine Scaffold and Their Derived Glycosides.
    Rahman AAHA; Nassar IF; Shaban AKF; El-Kady DS; Awad HM; El Sayed WA
    Mini Rev Med Chem; 2019; 19(13):1093-1110. PubMed ID: 30864522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.